Value
A growing and collaborative ecosystem
Accelerated innovation in R&D
Queensland is home to globally reputable universities, hospitals, academic centres of excellence, and cutting-edge clinical trial facilities. Our experienced research teams and clinicians foster an environment of high-quality patient care and groundbreaking clinical research, nurturing the next generation of researchers and practitioners. Queensland’s clinical trials ecosystem accelerates the translation of research into improved practices and technologies, supporting startups and scaleups.
Research and Development Tax Incentive Program
Eligible companies can take advantage of the Research and Development (R&D) Tax Incentive program with a cash refund of up to 43.5% on qualifying* R&D expenditure. The R&D Tax Incentive program provides targeted R&D tax offsets to encourage more companies to engage in research in Australia. The R&D tax incentive has two core components. Companies with an annual turnover of $20 million or less. Companies with an annual turnover of $20 million or more. Unlike similar programs in other countries, there is no requirement for companies in Australia to demonstrate year-on-year growth in their R&D expenditure to claim a tax benefit. It’s also not a requirement for the intellectual property from eligible R&D projects to be held in Australia. Learn more about the Research and Development Tax Incentive program.
Learn about the R&D Tax Incentive ProgramEligibility
Generally, activities conducted in Australia during early stage development or clinical trials (phases 0/I, II and III) are likely to meet the eligibility criteria.
There is no Investigational New Drug (IND) requirement in Australia allowing rapid entry into clinical trials under the Clinical Trials Notification scheme (CTN). The CTN is administered by the Therapeutic Goods Administration (TGA).
To find out about CTN, click on the link below.
